Ranbaxy Launches Asthma Inhalation Capsule in India
Pharma major Ranbaxy Laboratories Ltd Tuesday launched its branded inhalation capsules in India for the treatment of asthma.
A unique combination of long acting Beta2-agonist Formoterol and the most potent inhaled corticosteroid Fluticasone, the inhalation capsule Avessa is available as Rheocaps Avessa 100 mcg, Avessa 250 mcg, Avessa 500 mcg, depending on the severity of Asthma.
The product is to be used only with the Rheohaler - the world's first capsule-based multi-dose dry powder inhaler, Ranbaxy stated Tuesday.
"We are delighted to launch the world's first unique combination product Avessa in India, which reinforces our strong commitment to develop and introduce convenient solutions for asthmatic patients," said Sanjeev I. Dani, regional director of Ranbaxy for India and the Middle East.
Earlier this year, Ranbaxy had launched Osonide (Ciclesonide) Inhaler, a novel once-a-day product for asthma patients.
In May Ranbaxy entered into an in-licensing agreement for the Indian market with the Netherlands-based pharma company, Eurodrug Laboratories, for the asthma product Doxophylline - a novel Xanthine bronchodilator, sold under the brand name 'Synasma'.